Company intelligence / Profile preview

Sinovent

Shanghai, Shanghai, China

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Sinovent's lead program XNW1011 (BTK inhibitor) has completed a Phase 1 study showing favorable safety and pharmacokinetics and is advancing to Phase 2 in renal diseases. XNW27011 targeting Claudin 18.2 is in Phase 1 for solid tumors. The company also has preclinical assets covering oncology and anti-infectives[1][3][4].

Therapeutic areas: NephrologyMetabolic DisordersInfectious DiseasesGastroenterologyOncology
Modalities: Small moleculeAntibody-drug conjugatePROTAC-based therapy
Industry: Biotech

Partnerships

Everest MedicinesSinoMab BioScienceAlphamab Oncology

Beyond the preview

Go deeper on Sinovent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinovent.

Explore the full profile